Date:8/2/2011

.05)$
.03$
.05Net Income (loss) per share-diluted$
.02$
(0.05)$
.03$
.05Weighted average shares outstanding - basic35,44334,79035,31634,770Weighted average shares outstanding - diluted36,43934,79036,38934,770STAAR Surgical CompanyCondensed Consolidated Statements of Cash Flows(in 000's)Six Months EndedJuly 1,July 220112010Cash flows from operating activities:   Net income$
,161$
,902   Adjustments to reconcile net income to net cash provided by (used in) operating activities:Income from discontinued operations-(4,166)Depreciation of property and equipment598821Amortization of intangibles394399Amortization of discount-236Deferred income taxes118-Loss on early extinguishment of note payable-267Fair value adjustment of warrant(182)137Loss (gain) on disposal of property and equipment(14)2Stock-based compensation expense807649Change in net pension liability62157Other(32)112   Changes in working capital:Accounts receivable2631,040Inventories779777Prepaids, deposits and other current assets23272Accounts payable(273)(1,731)Other current liabilities(793)(5,338)Net cash used in operating activities of discontinued operations-(635)Net cash provided by (used in) operating activities2,911(5,099)Cash flows from investing activities:Proceeds from sale of subsidiary, net of transaction costs -11,824Release of restricted cash-7,337Acquisition of property and equipment(207)(202)Deposit to restricted escrow account-(136)Proceeds from sale of property and equipment26-Net change in other assets475Net cash used in investing activities of discontinued operations-(50)Net cash provided by (used in) investing activities(134)18,778Cash flows from financing activities:Repayment of notes payable-(5,000)Redemption of Series A preferred stock-(6,800)Repayment of capital lease obligations(228)(495)Proceeds from exercise of stock options1,216140Net cash used in financing activities of discontinued operations-(50)Net cash provided by (used in) financing activit
'/>"/>

SOURCE STAAR Surgical Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000
2. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
3. STAAR Surgical Launches Second Phase of Visian ICL Direct-to-Consumer Advertising Campaign
4. STAAR Surgical Enters Into Distribution Agreement With Ellex in Australia
5. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
6. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
7. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
8. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
9. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
10. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
11. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York